ea0099p95 | Endocrine-Related Cancer | ECE2024
Sazonova Daria
, Kutakov Nikita
, Lutsenko Alexander
, Przhiyalkovskaya Elena
, Troshina Ekaterina
Background: Immune checkpoint Inhibitors (ICIs) have revolutionized the treatment of vast array of cancers. Despite their efficacy, ICIs can cause various side effects related to the mechanism of action. Immune-related endocrine events (irEEs) are one of the most common immune-related adverse events (irAEs), accounting for 8.1% of all cases. We report two patients with durable responses to ICIs and concurrent serious irEEs.Case 1: A 58-year-old woman wit...